CN110760481A - Improved RPMI1640 culture medium and application thereof - Google Patents
Improved RPMI1640 culture medium and application thereof Download PDFInfo
- Publication number
- CN110760481A CN110760481A CN201911043694.6A CN201911043694A CN110760481A CN 110760481 A CN110760481 A CN 110760481A CN 201911043694 A CN201911043694 A CN 201911043694A CN 110760481 A CN110760481 A CN 110760481A
- Authority
- CN
- China
- Prior art keywords
- car
- cells
- concentration
- culture medium
- rpmi1640 medium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
- C12N2500/14—Calcium; Ca chelators; Calcitonin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
- C12N2500/16—Magnesium; Mg chelators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/34—Sugars
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/35—Polyols, e.g. glycerin, inositol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/70—Undefined extracts
- C12N2500/80—Undefined extracts from animals
- C12N2500/84—Undefined extracts from animals from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Abstract
The invention provides an improved RPMI1640 culture medium, which changes the concentration of sodium chloride and potassium chloride in the RPMI1640 culture medium. Compared with the RPMI1640 culture medium, the culture medium disclosed by the invention can keep normal proliferation of CAR-T cells when the CAR-T cells are cultured, can reduce exhaustion of the CAR-T cells, enhances anti-tumor activity of the CAR-T cells, and has a good application prospect.
Description
Technical Field
The invention relates to the field of biomedical cell therapy, in particular to an improved RPMI1640 culture medium and application thereof.
Background
According to the statistics of global cancer reports, blood tumors mainly including leukemia, lymphoma, multiple myeloma and the like seriously threaten the life and health of human beings, are the eighth most common malignant tumors, and have the increasing incidence rate year by year. Immunotherapy has brought new hopes for the treatment of human blood tumor in recent years, wherein the immunotherapy using genetic engineering technology to modify T cells to express antibodies capable of recognizing tumor antigens, target tumor cells, activate T cells and kill tumor cells, i.e., chimeric Antigen Receptor T cells (CAR-T) is the most promising tumor immunotherapy and research hotspot in recent years. Currently, CAR-T cell immunotherapy has achieved exciting results in clinical hematological disorders, and there are two CAR-T cell products against the CD19 antigen from B cell leukemia that have been approved by the FDA for clinical treatment of leukemia.
The main processes of CAR-T cell therapy are: isolating immune T cells from peripheral blood of a cancer patient; preparing CAR-T cells through in vitro gene modification; further expanding the CAR-T cells in vitro cell culture medium; the expanded CAR-T cells are reinfused back into the patient.
The conventional medium used for the in vitro culture of CAR-T cells is RPMI1640 medium. However, during the expansion of CAR-T cells in vitro, T cells are depleted, affecting the killing ability of T cells.
Disclosure of Invention
In view of the above, the invention provides an improved RPMI1640 culture medium, which changes the concentration of potassium ions and sodium ions in the RPMI1640 culture medium, so as to overcome the defect that CAR-T cells are easy to be exhausted in vitro culture and improve the tumor killing capacity of the CAR-T cells.
The technical scheme of the invention is realized as follows:
in a first aspect, the present invention provides an improved RPMI1640 medium, wherein the concentration of sodium chloride in the RPMI1640 medium is adjusted to 53.4-63.4mM, the concentration of potassium chloride is adjusted to 45.3-55.3mM, and the total concentration of potassium ions and sodium ions is 108.7 mM.
On the basis of the technical scheme, preferably, the modified RPMI1640 culture medium comprises the following components: glycine 0.133mM, L-arginine 1.15mM, L-asparagine 0.379mM, L-aspartic acid 0.15mM, L-cysteine 0.208mM, L-glutamic acid 0.136mM, L-alanylglutamine 2.05mM, L-histidine 0.0968mM, L-hydroxyproline 0.153mM, L-isoleucine 0.382mM, L-leucine 0.382mM, L-lysine hydrochloride 0.219mM, L-methionine 0.101mM, L-phenylalanine 0.0909mM, L-proline 0.174mM, L-serine 0.286mM, L-threonine 0.168mM, L-tryptophan 0.0245mM, L-tyrosine 0.111mM, L-valine 0.171mM, biotin 0.00082mM, choline chloride 0.0214mM, D-calcium pantothenate 0.000524mM, folic acid 57 mM, nicotinamide 0.0082mM, p-aminobenzoic acid 0.0073mM, pyridoxine 0.82 mM, pyridoxine hydrochloride 82mM, 0.000532mM of riboflavin, 0.00297mM of thiamine hydrochloride, 0.0000037mM of vitamin B120.0000037mM of i-inositol, 0.194mM of calcium nitrate tetrahydrate, 0.407mM of magnesium sulfate heptahydrate, 23.81mM of sodium bicarbonate, 5.63mM of anhydrous disodium hydrogen phosphate, 53.4-63.4mM of sodium chloride, 45.3-55.3mM of potassium chloride, 11.11mM of D-glucose, 0.00326mM of reduced glutathione and 0.0133mM of phenol red.
Based on the above technical scheme, preferably, the concentration of the sodium chloride is 53.4mM, and the concentration of the potassium chloride is 55.3 mM.
In a second aspect, the invention provides the use of a modified RPMI1640 medium according to the first aspect in CAR-T cell culture.
In a third aspect, the invention also provides a method of CAR-T cell culture comprising: CAR-T cells were cultured using the modified RPMI1640 medium of the first aspect.
Compared with the prior art, the improved RPMI1640 culture medium has the following beneficial effects:
(1) the improved culture medium changes the metabolic environment of the CAR-T cells by changing the potassium ion concentration of the RPMI1640 culture medium, so that the CAR-T cells are in a stem cell state in the amplification process, excessive activation of the CAR-T cells is avoided, and apoptosis of the CAR-T cells is reduced, so that the killing function of the CAR-T cells is improved;
(2) the improved culture medium only changes the concentration of potassium ions and sodium ions of the RPMI1640 culture medium, fetal bovine serum is only added on the basis when the CAR-T cells are cultured, and growth factors such as various amino acids and vitamins are not required to be additionally added, so that the CAR-T cells can keep a good proliferation state, the apoptosis of the CAR-T cells is reduced, the tumor killing capability of the CAR-T cells is improved, the operation is simple and convenient, and the effect is obvious.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below, it is obvious that the drawings in the following description are only some embodiments of the present invention, and for those skilled in the art, other drawings can be obtained according to the drawings without creative efforts.
FIG. 1 shows the proliferation of CD19-CAR-T cells in different media according to the invention;
FIG. 2 shows the expression of Fas (CD95) in CD19-CAR-T cultured in different media according to the present invention;
FIG. 3 shows the tumoricidal effect of CD19-CAR-T cultured in different media according to the invention.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be obtained by a person skilled in the art without any inventive step based on the embodiments of the present invention, are within the scope of the present invention.
Interpretation of terms:
chimeric Antigen Receptor (CAR): is a central component of CAR-T, conferring on T cells the ability of Human Lymphocyte Antigen (HLA) to recognize tumor antigens in an independent manner, which enables CAR-engineered T cells to recognize a broader range of targets than native T cell antigen receptors (TCRs). The basic design of a CAR includes a tumor-associated antigen (TAA) binding region (usually the scFV fragment from the antigen binding region of a monoclonal antibody), an extracellular hinge region, a transmembrane region, and an intracellular signaling region. The choice of antigen of interest is a key determinant for the specificity, efficacy of the CAR and safety of the genetically engineered T cells themselves.
CAR-T cells: chimeric antigen receptor T cells.
CD 19-CAR-T: chimeric antigen receptor genetically modified T cells targeting the CD19 molecule.
CD 3: in immunology, the co-receptor of CD3 (cluster of differentiation 3) T cells is a protein complex, which consists of four distinct chains. In mammals, the complex contains one CD3 γ chain, one CD3 δ chain, and two CD3 epsilon chains. These chains have T lymphocytes called a molecular parat cell receptor (TCR) and zeta-chains to generate activation signals. The TCR, zeta chain and CD3 molecules together form a T cell receptor complex.
Pbmc (periheral blood mononar cell): peripheral blood mononuclear cells are cells having a single nucleus in peripheral blood, and include lymphocytes, monocytes, and the like.
All raw materials in the improved RPMI1640 culture medium disclosed by the invention are ultrapure or analytically pure reagents which meet the second division of the United states Pharmacopeia, national Standard chemical reagents or Chinese pharmacopoeia 2010 edition so as to meet the requirements of clinical safety and reasonability.
RPMI1640 medium was purchased from Gibco, CD3 antibody was purchased from Milteny biotec, anti-fas antibody was purchased from Biolegend, interleukin 2(IL-2) was purchased from Peprotech, HEK293T cells and Raji cells were purchased from ATCC cell bank, and LDH kit was purchased from Sigma. The lentiviral plasmid for CD19 CAR-T was constructed by the laboratory.
The invention is further illustrated by the following examples:
the media components of examples 1-3 and comparative examples are detailed in the following table:
examples 1-3 the medium was modified RPMI1640 medium, as indicated by MTM1-MTM 3; the comparative example is RPMI1640 medium.
The preparation method of each medium in the above examples 1 to 3 and comparative example includes: mixing the components of the culture medium with high-purity sterilized water in proportion, shaking and uniformly mixing for 1 hour at 4 ℃, and then filtering and sterilizing through a filter membrane of 0.22 mu m for later use.
Each of the following experiments using the culture media of examples 1-3 and comparative examples was repeated in T cells of three healthy adults.
PBMC and T cell isolation: peripheral blood from healthy adult donors was drawn, PBMC separated using Ficoll, followed by T cell separation using anti-CD3 magnetic beads.
The preparation method of the CD19-CAR-T cell comprises the following steps: transfecting HEK293T cells with a lentiviral plasmid of CD19-CAR-T, collecting cell culture supernatant after 5 days, and preparing lentivirus; t cells were transfected with MOI 5:1 (lentivirus: T cells).
The culture medium of example 1-example 3 and comparative example was used for culturing CD19-CAR-T cells as follows: the CD19-CAR-T cells were resuspended in the culture media of examples 1-3 and comparative examples, 10% of fetal bovine serum, 30ng/mL of OKT3 antibody and 4 allogeneic PBMCs (1: 200 volume ratio of T cells to PBMCs) were added simultaneously, and the seeding density of CD19-CAR-T cells was adjusted to 1X 105cell/mL, 5% CO2And culturing in an incubator at 37 ℃. In the culture process, 200IU of IL-2 is added every other day for 12 days.
The CD19-CAR-T cells cultured according to the above steps by using the culture media of example 1-example 3 and comparative example were tested, specifically:
1) cells cultured for 6 days and 12 days were collected and counted by trypan blue staining.
2) CD19-CAR-T cells cultured for 12 days were stained with anti-Fas antibody, and the expression rate of cell surface death receptor factor Fas (CD95) was examined by flow cytometry.
3) The CD19-CAR-T cells cultured for 12 days and cultured leukemia Raji cells are co-cultured according to the volume ratio of 3:1, and the tumor killing rate of the CD19-CAR-T cells is detected and calculated by using an LDH kit.
The test results are as follows:
1) cell proliferation status
Cell proliferation after culture of CD19-CAR-T cells using the media of example 1-example 3 and comparative example is shown in figure 1, and the results show that the modified media MTM1, MTM2 and MTM3 have no effect on the proliferation of CD19 CAR-T cells compared to RPMI1640 medium.
2) Results of detection of Fas (CD95) expression Rate
The expression of Fas (CD95) in CD19-CAR-T cultured in the culture media of example 1-example 3 and comparative example is shown in FIG. 2, and the modified culture media MTM1 and MTM2 can significantly reduce the expression of Fas (CD95) on the surface of CD19-CAR-T cells.
3) Detection result of CD19-CAR-T cell tumor killing rate
The tumor killing rate of CD19-CAR-T cultured by the culture media of example 1-example 3 and comparative example is shown in FIG. 3, and after the CD19 CAR-T cultured by the modified culture media MTM1 and MTM2 is co-cultured with leukemia cells, the tumor killing capacity of CD19-CAR-T cells can be remarkably enhanced.
Compared with the RPMI1640 culture medium, the improved RPMI1640 culture medium provided by the invention has no influence on the proliferation of CD19-CAR-T cells when the CD19-CAR-T cells are cultured, but can down-regulate the expression of Fas (CD95) on the surface of the CD19-CAR-T cells, so that Fas-mediated T cell apoptosis is inhibited, and the tumor killing capacity of the CD19-CAR-T cells is remarkably enhanced.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents, improvements and the like that fall within the spirit and principle of the present invention are intended to be included therein.
Claims (5)
1. A modified RPMI1640 medium, which is characterized in that: the concentration of sodium chloride in the medium was 53.4-63.4mM, the concentration of potassium chloride was 45.3-55.3mM, and the total concentration of potassium ions and sodium ions was 108.7 mM.
2. The modified RPMI1640 medium of claim 1, comprising the following components: glycine 0.133mM, L-arginine 1.15mM, L-asparagine 0.379mM, L-aspartic acid 0.15mM, L-cysteine 0.208mM, L-glutamic acid 0.136mM, L-alanylglutamine 2.05mM, L-histidine 0.0968mM, L-hydroxyproline 0.153mM, L-isoleucine 0.382mM, L-leucine 0.382mM, L-lysine hydrochloride 0.219mM, L-methionine 0.101mM, L-phenylalanine 0.0909mM, L-proline 0.174mM, L-serine 0.286mM, L-threonine 0.168mM, L-tryptophan 0.0245mM, L-tyrosine 0.111mM, L-valine 0.171mM, biotin 0.00082mM, choline chloride 0.0214mM, D-calcium pantothenate 0.000524mM, folic acid 57 mM, nicotinamide 0.0082mM, p-aminobenzoic acid 0.0073mM, pyridoxine 0.82 mM, pyridoxine hydrochloride 82mM, 0.000532mM of riboflavin, 0.00297mM of thiamine hydrochloride, 0.0000037mM of vitamin B120.0000037mM of i-inositol, 0.194mM of calcium nitrate tetrahydrate, 0.407mM of magnesium sulfate heptahydrate, 23.81mM of sodium bicarbonate, 5.63mM of anhydrous disodium hydrogen phosphate, 53.4-63.4mM of sodium chloride, 45.3-55.3mM of potassium chloride, 11.11mM of D-glucose, 0.00326mM of reduced glutathione and 0.0133mM of phenol red.
3. The modified RPMI1640 medium of claim 1, wherein: the concentration of the sodium chloride is 53.4mM, and the concentration of the potassium chloride is 55.3 mM.
4. Use of the modified RPMI1640 medium of claim 1 in CAR-T cell culture.
5. A method of CAR-T cell culture, characterized in that: culturing CAR-T cells using the modified RPMI1640 medium of claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911043694.6A CN110760481B (en) | 2019-10-30 | 2019-10-30 | Improved RPMI1640 culture medium and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911043694.6A CN110760481B (en) | 2019-10-30 | 2019-10-30 | Improved RPMI1640 culture medium and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110760481A true CN110760481A (en) | 2020-02-07 |
| CN110760481B CN110760481B (en) | 2021-04-02 |
Family
ID=69334603
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911043694.6A Active CN110760481B (en) | 2019-10-30 | 2019-10-30 | Improved RPMI1640 culture medium and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110760481B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113293130A (en) * | 2020-08-11 | 2021-08-24 | 河南省肿瘤医院 | Culture method of tumor specific T cells |
| CN117070454A (en) * | 2023-10-18 | 2023-11-17 | 北京细胞治疗集团有限公司 | Preparation method of CAR-T cells |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104818248A (en) * | 2015-03-25 | 2015-08-05 | 苏州佰通生物科技有限公司 | Immunocyte culture medium, and culture method and application of immunocytes |
| CN106834229A (en) * | 2017-01-25 | 2017-06-13 | 华东理工大学 | For the serum free medium of people's immunologic cytotoxicity cell expansion ex vivo |
| CN108059675A (en) * | 2017-12-12 | 2018-05-22 | 武汉波睿达生物科技有限公司 | The structure for recombinating PG9-CAR molecules and its application in HIV-1 infection cells are removed |
| WO2018178069A1 (en) * | 2017-03-31 | 2018-10-04 | Boehringer Ingelheim International Gmbh | Perfusion medium |
| CN110157680A (en) * | 2019-05-08 | 2019-08-23 | 浙江大学 | Improve the cell culture processes of Chimeric antigen receptor T cell curative effect and duration of action |
-
2019
- 2019-10-30 CN CN201911043694.6A patent/CN110760481B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104818248A (en) * | 2015-03-25 | 2015-08-05 | 苏州佰通生物科技有限公司 | Immunocyte culture medium, and culture method and application of immunocytes |
| CN106834229A (en) * | 2017-01-25 | 2017-06-13 | 华东理工大学 | For the serum free medium of people's immunologic cytotoxicity cell expansion ex vivo |
| WO2018178069A1 (en) * | 2017-03-31 | 2018-10-04 | Boehringer Ingelheim International Gmbh | Perfusion medium |
| CN108059675A (en) * | 2017-12-12 | 2018-05-22 | 武汉波睿达生物科技有限公司 | The structure for recombinating PG9-CAR molecules and its application in HIV-1 infection cells are removed |
| CN110157680A (en) * | 2019-05-08 | 2019-08-23 | 浙江大学 | Improve the cell culture processes of Chimeric antigen receptor T cell curative effect and duration of action |
Non-Patent Citations (6)
| Title |
|---|
| SIGMA LIFE SCIENCE: "《Sigma Cell Culture Manual 2011-2014》", 31 December 2014 * |
| WANG D 等: "In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function", 《J VIS EXP》 * |
| XU H等: "Influence of various medium environment to in vitro human T cell culture", 《IN VITRO CELL DEV BIOL ANIM》 * |
| 任凯丽: "CAR-T免疫治疗的研究进展", 《科学技术创新》 * |
| 刘延众 等: "靶向CD33的CAR修饰的NK92细胞对CD33~+急性髓系白血病细胞的杀伤作用", 《中国肿瘤生物治疗杂志》 * |
| 王轩 等: "细胞外钾离子对小鼠神经干细胞凋亡的影响", 《立体定向和功能性神经外科杂志》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113293130A (en) * | 2020-08-11 | 2021-08-24 | 河南省肿瘤医院 | Culture method of tumor specific T cells |
| CN117070454A (en) * | 2023-10-18 | 2023-11-17 | 北京细胞治疗集团有限公司 | Preparation method of CAR-T cells |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110760481B (en) | 2021-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200239845A1 (en) | Expanded nk cells | |
| US7410773B2 (en) | Method of preparing an undifferentiated cell | |
| Oberschmidt et al. | Development of automated separation, expansion, and quality control protocols for clinical-scale manufacturing of primary human NK cells and alpharetroviral chimeric antigen receptor engineering | |
| JP2022058504A (en) | Nk cells exhibiting adaptive phenotype and methods for preparing and using the same | |
| CN110760481B (en) | Improved RPMI1640 culture medium and application thereof | |
| US20230133064A1 (en) | T cell manufacturing process | |
| CN115651903B (en) | High-lethality immune cell population, and culture method, reagent composition and application thereof | |
| WO2021222479A9 (en) | Methods for culturing cells | |
| CN115558641B (en) | High-purity effector immune cell population, culture method, reagent composition and application thereof | |
| CN112795536A (en) | Culture method of human T cells and serum-free medium composition | |
| EP1233058A1 (en) | Method of proliferating natural killer cells | |
| WO2023216799A1 (en) | Human nkt cell line and use thereof | |
| US20030138947A1 (en) | Method of preparing an undifferentiated cell | |
| TWI757785B (en) | Ciml nk cells and methods therefor | |
| JP2024512029A (en) | Methods and compositions for T cell co-culture efficacy assays and use with cell therapy products | |
| Onlamoon et al. | Optimization of in vitro expansion of macaque CD4+ T cells using anti‐CD3 and co‐stimulation for autotransfusion therapy | |
| WO2021006876A1 (en) | Ciml nk cells and methods therefor | |
| Fischkoff et al. | Induction of differentiation of the human leukemia cell line, KU812 | |
| WO2019217512A1 (en) | Compositions and methods for culturing and expanding cells | |
| Thitilertdecha et al. | Determination of cell expansion and surface molecule expression on anti‐CD3/28 expanded CD4+ T cells | |
| WO2021247555A1 (en) | Induced regulatory t cells, methods of production, and uses thereof | |
| CN114836380A (en) | Composition for enhancing lethality of NK (natural killer) cells to tumor cells and application of composition | |
| CN117683715A (en) | Method for preparing type I NKT cells by using umbilical cord blood | |
| WO2021123255A1 (en) | Improved process for culturing tumor-infiltrating lymphocytes for therapeutic use | |
| Dann et al. | A new platelet lysate alternative to serum for ex vivo transduction and expansion of human T cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |